CC-11050

Drug Celgene Corporation
Total Payments
$24,625
Transactions
3
Doctors
1
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2019 $194.61 2 1
2018 $24,431 1 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $24,546 2 99.7%
Food and Beverage $79.11 1 0.3%

Payments by Type

Research
$24,546
2 transactions
General
$79.11
1 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CC-11050 After Single and Multiple Doses of CC-11050 and Evaluate CC-11050 Pharmacokinetics Under Fasted and Fed Conditions and After Administration of CC-11050 Alone Compared to Co-administration With a Proton Pump Inhibitor in Healthy Adult Subjects (CC-11050-CP-010) Celgene Corporation $115.50 0

Top Doctors Receiving Payments for CC-11050

Doctor Specialty Location Total Records
Unknown St Louis, MO $24,546 2
Mahesh Shah Cardiovascular Disease Prince Frederick, MD $79.11 1

About CC-11050

CC-11050 is a drug associated with $24,625 in payments to 1 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.

Payment data is available from 2018 to 2019. In 2019, $194.61 was paid across 2 transactions to 1 doctors.

The most common payment nature for CC-11050 is "Unspecified" ($24,546, 99.7% of total).

CC-11050 is associated with 1 research study, including "A Phase 1, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CC-11050 After Single and Multiple Doses of CC-11050 and Evaluate CC-11050 Pharmacokinetics Under Fasted and Fed Conditions and After Administration of CC-11050 Alone Compared to Co-administration With a Proton Pump Inhibitor in Healthy Adult Subjects (CC-11050-CP-010)" ($115.50).